Idorsia首席执行官,负责概述在保健会议上维持业务的战略。 Idorsia CEO to outline strategies for maintaining operations at healthcare conference.

Idorsia Ltd是一家瑞士生物制药公司,定于2025年1月15日出席J.P.摩根保健会议。 Idorsia Ltd, a Swiss biopharmaceutical company, is set to present at the J.P. Morgan Healthcare Conference on January 15, 2025. 首席执行官André C. Muller将讨论维持业务的战略,包括全球保有权利、筹资和结构调整。 CEO André C. Muller will address strategies for maintaining operations, including global rights for aprocitentan, funding, and restructuring. 重点是将商业努力与QUVIVIQ和伙伴资产的特许权使用费相结合的双重收入模式。 The focus is on a dual revenue model combining commercial efforts with QUVIVIQ and royalties from partnered assets. Idorsia的目标是通过诸如处方支助、财务纪律和为失眠和多发性硬化症等病症制定治疗方法等战略优先事项来推动价值。 Idorsia aims to drive value through strategic priorities like prescription support, financial discipline, and developing treatments for conditions like insomnia and multiple sclerosis.